After months of hectic activity, the IPO market experienced a lull in the Thanksgiving week, but it is still headed for a record year though the rush led by the technology and healthcare sectors is probably cooling down. The momentum is expected to pick up in the coming days as many aspirants would seek to go public before the holidays.
One of the major upcoming events is the listing of Nuvectis Pharma, Inc., a biotechnology firm focused on the development of novel targeted therapeutics for the treatment of cancer.
The company intends to offer around 2.3 million shares at an estimated price between $12 and $14. At the mid-point of the range, it would yield around $30 million. The offering will be managed by ThinkEquity, the sole book-runner. Once approved by regulators, the stock will list on the Nasdaq stock exchange under the ticker symbol NVCT.
Targets $30 Mln
The amount to be raised through the offering will mainly be used for advancing the clinical trials of Nuvectis’ lead candidate NXP800 and second treatment NXP900, which are indicated for the treatment of different types of cancer. The company was founded in 2020 and is currently led by chief executive officer Ron Bentsur.
It is estimated that oncology, Nuvectis’ core business, is the fastest-growing pharmaceutical segment, wherein several therapeutic needs still remain unmet. The company’s focus on specialty care should help it tap into opportunities in this healthcare area. Moreover, there has been continued innovation in cancer research, thanks to the steady flow of funds — a trend that bodes well for early-stage drug developers like Nuvectis.
Though it is a highly promising area, the market for oncology pharmaceuticals is highly competitive. It goes without saying that the future prospects of the company would depend on the successful completion and commercial launch of its two leading drug candidates, which is not guaranteed.
Nuvectis is a phase-I ready company, and its formulations need to successfully complete the critical phase-II trials before hitting the market. Also, the intense research and development activities associated with clinical programs would require heavy investments.
The company raised around $15 million in a funding round earlier this year. Of that, around $3.5 million was used as upfront payment in connection with an exclusive licensing agreement for NXP800. Later, a similar amount was paid as upfront payment for the licensing agreement related to NXP900. As of September 30, the company had a cash and cash equivalents balance of $6.8 million.
In the nine months ended September 30, 2021, Nuvectis incurred a net loss of $10.63 million or $2.54 per share. The company did not generate any revenue during that period.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings
Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop
Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported
Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of